Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR5088903

—

a8e53be5-a813-5bce-8a28-365f40bbfe36

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INFLAMMATORY_RESPONSE+0.400
  • PANCREAS_BETA_CELLS+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.400
  • ALLOGRAFT_REJECTION+0.300
  • ESTROGEN_RESPONSE_LATE+0.300
  • OXIDATIVE_PHOSPHORYLATION+0.300
  • CHOLESTEROL_HOMEOSTASIS+0.200
  • COAGULATION+0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
  • KRAS_SIGNALING_DN+0.200

Top 10 suppressed

  • MITOTIC_SPINDLE-0.600
  • WNT_BETA_CATENIN_SIGNALING-0.500
  • E2F_TARGETS-0.400
  • G2M_CHECKPOINT-0.400
  • HEDGEHOG_SIGNALING-0.400
  • MYC_TARGETS_V2-0.400
  • UNFOLDED_PROTEIN_RESPONSE-0.300
  • UV_RESPONSE_DN-0.300
  • PI3K_AKT_MTOR_SIGNALING-0.200
  • PROTEIN_SECRETION-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-18-3406-01A-01R-0980-07
lung-landscapes@6
—cohortSQ10.801
2MNG757
mng-umap@100
——0.791
3MNG1232
mng-umap@100
——0.777
4SRR5088872
melanoma-umap@29
——0.772
5ERR2598269
medullo-epn-umap@date-based
fetalfetal0.766
6TCGA-34-5234-01A-01R-1635-07
lung-landscapes@6
—cohortSQ10.766
7ERR2598335
medullo-epn-umap@date-based
fetalfetal0.766
8TCGA-OL-A66L-01A-12R-A31O-07
breast-umap@18
—B0.762
9MDT-AP-0572
medullo-epn-umap@date-based
MedMedulloblastoma0.759
10TCGA-A7-A3IY-01A-21R-A21T-07
breast-umap@18
—C0.752

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
PANCREAS_BETA_CELLS0.400Cobimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.300Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.300Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.200Remibrutinib— uncovered
COAGULATION0.200Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.200Inavolisib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered
KRAS_SIGNALING_UP0.200Inavolisib— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.200Inavolisib— uncovered
UV_RESPONSE_UP0.200Idelalisib— uncovered
ANGIOGENESIS0.100Remibrutinib— uncovered
APOPTOSIS0.100Idelalisib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.100Inavolisib— uncovered
HYPOXIA0.100Idelalisib— uncovered
IL2_STAT5_SIGNALING0.100Idelalisib— uncovered